GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zhejiang Medicine Co Ltd (SHSE:600216) » Definitions » Cash Conversion Cycle

Zhejiang Medicine Co (SHSE:600216) Cash Conversion Cycle : 138.09 (As of Mar. 2025)


View and export this data going back to 1999. Start your Free Trial

What is Zhejiang Medicine Co Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

Zhejiang Medicine Co's Days Sales Outstanding for the three months ended in Mar. 2025 was 67.51.
Zhejiang Medicine Co's Days Inventory for the three months ended in Mar. 2025 was 149.1.
Zhejiang Medicine Co's Days Payable for the three months ended in Mar. 2025 was 78.52.
Therefore, Zhejiang Medicine Co's Cash Conversion Cycle (CCC) for the three months ended in Mar. 2025 was 138.09.


Zhejiang Medicine Co Cash Conversion Cycle Historical Data

The historical data trend for Zhejiang Medicine Co's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zhejiang Medicine Co Cash Conversion Cycle Chart

Zhejiang Medicine Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cash Conversion Cycle
Get a 7-Day Free Trial Premium Member Only Premium Member Only 125.59 93.33 108.46 121.83 118.95

Zhejiang Medicine Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 101.58 110.52 102.29 137.76 138.09

Competitive Comparison of Zhejiang Medicine Co's Cash Conversion Cycle

For the Drug Manufacturers - Specialty & Generic subindustry, Zhejiang Medicine Co's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zhejiang Medicine Co's Cash Conversion Cycle Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Zhejiang Medicine Co's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where Zhejiang Medicine Co's Cash Conversion Cycle falls into.


;
;

Zhejiang Medicine Co Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

Zhejiang Medicine Co's Cash Conversion Cycle for the fiscal year that ended in Dec. 2024 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=56.05+139.86-76.96
=118.95

Zhejiang Medicine Co's Cash Conversion Cycle for the quarter that ended in Mar. 2025 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=67.51+149.1-78.52
=138.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Zhejiang Medicine Co  (SHSE:600216) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


Zhejiang Medicine Co Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of Zhejiang Medicine Co's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


Zhejiang Medicine Co Business Description

Traded in Other Exchanges
N/A
Address
Comprehensive Building, No. 398 Mahuan Road, 3rd Floor, Building A, Binhai New City, Shaoxing, CHN, 312366
Zhejiang Medicine Co Ltd is a china-based pharmaceutical company. The company manufactures fat-soluble vitamins, vitamins, quinolones, and antibiotic-resistant antibiotics, vitamin E, natural vitamin E, beta-carotene, cantharidin, vancomycin hydrochloride, and teicoplanin.
Executives
Zhu Jin Lin senior management
Chu Zhen Hua Director
Liang Bi Rong Director
Yu Yu Qing Director
Ping Jian Hong senior management
An Yong Bin senior management
Wang Xiao Ping senior management
Liang Li Ping senior management
Li Qi Rong senior management
Zhu Shao Ming Supervisors
Wang Hong Wei senior management
Zhang Ding Feng senior management
Ma Wen Xin Director
Zhao Jun Xing senior management
Lv Yong Hui Director

Zhejiang Medicine Co Headlines

No Headlines